Biomerica

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

IRVINE, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced financial results for its second quarter of fiscal year 2021, which ended November 30, 2020.

Biomerica Reports Fiscal 2021 Second Quarter Financial Results and Provides Business Update

Biomerica (BMRA) news for Tuesday concerning its rapid test for the novel coronavirus coming to new countries has BMRA stock on the rise. The post Biomerica News: 10 Things for Potential BMRA Stock Investors to Know Today appeared first on InvestorPlace.

Biomerica News: 10 Things for Potential BMRA Stock Investors to Know Today

IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it has received CE Mark for its new COVID-19 Rapid Antigen Test for detection of COVID-19 infection. The Company has already received its first European orders and plans to ship the first part of these orders in the coming weeks. The Company will now begin marketing this product broadly in Europe and other regions outside of the US.

Biomerica's Fast 15-Minute Simple to Use Covid-19 Antigen Rapid Test Receives CE Mark

IRVINE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it is nearing completion of patient enrollment in the endpoint clinical trial for its InFoods® Irritable Bowel Syndrome (“IBS”) diagnostic-guided therapy (“DGT”). This double-blinded, randomized, controlled clinical trial is validating the Biomerica InFoods® IBS test to manage the debilitating pain and suffering of patients diagnosed with IBS. Utilizing an antibody guided blood test, the InFoods® IBS product identifies patient-specific foods that may alleviate IBS symptoms when eliminated from the diet.

Biomerica's InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

IRVINE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August 31, 2020.

Biomerica Reports Fiscal 2021 1st Quarter Financial Results

IRVINE, Calif., Sept.  01, 2020  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year ended May 31, 2020 were $6.7 million  versus net sales of $5.2 million in fiscal 2019.  This represents an increase of $1.5 million, or 28.7%.  Net loss was $2.3 million for fiscal 2020 compared to net loss of $2.4 million for fiscal 2019.  Research and Development investment was $1.9 million for fiscal year 2020 compared to $1.7 million the previous year, an increase of over 13%.  Year-end cash and cash equivalents were $8.6 million in fiscal 2020 versus $0.7 million in fiscal 2019 while current assets were $14.8 million in fiscal 2020 versus $4.5 million in fiscal 2019.

Biomerica Reports Fiscal Year End May 31, 2020 Financial Results

IRVINE, Calif., Aug.  31, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years of dedicated service, Ms. Moore has decided to retire and pursue personal interests. Ms. Moore will remain an employee of the Company during a transition period to ensure a smooth transition. Ms. Moore, who also serves as a member of the Board of Directors (the “Board”) and Corporate Secretary, will continue to serve as a member of the Board and as Corporate Secretary until the Company’s Annual Meeting on December 10, 2020. At that time, Ms. Moore will also be leaving the Board.

Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors

IRVINE, Calif., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for Biomerica’s second U.S. patent pertaining to the Company’s InFoods® technology platform that offers a revolutionary new way to treat patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application #16/385,322 contains numerous claims that broadly cover the method that enables physicians to identify patient specific foods (e.g. pork, milk, shrimp, broccoli, chickpeas, etc.), that when removed may alleviate or improve an individual's IBS symptoms, such as constipation, diarrhea, bloating, severe cramping, pain and indigestion.

Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS) and Provides Progress Update on COVID-19 antibody tests

IRVINE, Calif., July  22, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that it has filed a new three year shelf registration statement on Form S-3 with the United States Securities and Exchange Commission (“SEC”) to replace its previous three year shelf registration statement, which was declared effective by the SEC in July 2017.

Biomerica Announces Filing of New Three Year Shelf Registration Statement

AEGON

Arcimoto

Gaia

Garrett Motion

Harmony Gold Mining Co Ltd

Nomura Holdings

Here are seven cheap stocks to buy in the second half of the year. They come with risk, but are likely to offer head-turning reward potential, too.

The 7 Best Cheap Stocks Under $10 Right Now

Biomerica's COVID-19 Test Ignite The Market

IRVINE, Calif., June  29, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has signed a definitive agreement with the University of Texas Health Science Center at Houston (“UTH”) to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. The University of Texas Health Science Center at Houston is the fifth large medical center to be part of the InFoods® clinical trial which includes:  Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist and the University of Michigan as primary enrollment centers. UTH can now begin enrollment of patients in this trial.

The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial

IRVINE, Calif., June  16, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the detection of antibodies that identify if a person has been infected with the novel coronavirus (COVID-19).  Antibody testing can be an important next step in opening the economy to tell people if they have been previously infected.  This is the third COVID-19 antibody test introduced by the Company. The other two, which are finger-prick rapid tests, are actively being sold outside of the US and have been well received.  The Company also intends to obtain a CE mark to market and sell this ELISA laboratory test outside the US.

Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19

IRVINE, Calif., June  01, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced they have signed definitive agreements with Mayo Clinic to join the clinical trial for Biomerica’s new InFoods® diagnostic-guided therapy (DGT), designed to alleviate Irritable Bowel Syndrome (IBS) symptoms.  Mayo Clinic is joining Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist and the University of Michigan as primary enrollment centers for this study. Mayo Clinic can now begin enrollment of patients in this trial.

Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial

IRVINE, Calif., May  07, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has received a CE mark and launched a new high-volume production version of its COVID-19 IgG/IgM Rapid Test (a finger prick blood test with results in 10 minutes, that can be performed by trained professionals anywhere) being sold in countries outside the US.  This new high-volume version of the disposable serology test allows the company to ramp up production utilizing a proprietary card system that eliminates most plastic. The high-volume production version of this test is intended for larger customers doing high-volume screenings. This version also has the benefit of being environmentally friendly.

Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution

Biomerica, Inc. (NASDAQ: BMRA) shares are trading higher after the company announced it has signed two definitive agreements with Mount Sinai Medical School in NY to scale-up a laboratory version serological test for coronavirus that enables high-volume screenings in labs.

Why Biomerica's Stock Is Trading Higher Today

IRVINE, Calif., April  02, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has signed two separate definitive license agreements with Mount Sinai’s Icahn School of Medicine in New York to license technologies pertaining to a laboratory version serological test for SARS-CoV-2 (“COVID-19”) virus infection which have been developed at Mount Sinai. This test uses the ELISA microplate format that can run on existing open system equipment found in most hospitals and clinical laboratories in the United States.

Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs

Shares of micro-cap Biomerica, Inc. (NASDAQ: BMRA) were advancing strongly for the second straight session Thursday thanks to a late Tuesday announcement from the biomedical technology company regarding its COVID-19 test.

The $10, 10-Minute COVID-19 Test Sending Biomerica Soaring 600% In 2 Days

IRVINE, Calif., March  17, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced it has commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test (a finger prick blood test with results in 10 minutes, that can be performed by trained professionals anywhere, e.g. airports, schools, work, pharmacies and doctors’ offices) to countries outside the US. Evaluation test kits have been requested by Ministries of Health in multiple countries through the Company’s distribution partners who are working with their government agencies to assess the tests and forecast demand. This disposable point-of-care serology test is different than the current polymerase chain reaction (PCR) tests in that initial studies indicate that serology tests can identify if someone has been exposed to the COVID-19 virus, and can further detect if a person was recently infected with the disease even if they have never shown or are no longer showing symptoms. This can help health agencies focus on prior contacts of persons previously infected. Existing PCR tests generally only show positive if a person is currently infected and the virus is still present. Furthermore, PCR tests require patient samples to be sent to a lab, thus increasing the cost of the test and reducing the speed to obtain a result. Biomerica’s test could also be used in conjunction with the PCR test by rapidly pre-screening larger groups of individuals, who if tested positive could be further tested using a PCR test for verification.

Biomerica Begins Shipping Samples of 10 Minute Test for COVID-19 Virus Exposure

IRVINE, Calif., Feb.  26, 2020  (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) (the “Company” or “Biomerica”) announced today that the Company completed a private placement of $2 million of convertible preferred stock with Palm Global Small Cap Master Fund LP ("Palm").  The preferred shares are initially convertible into shares of the Company's common stock at a price of $3.50 per share.  This represents a premium to the market price of the Company’s common stock at the time of closing.

Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund

IRVINE, Calif., Jan.  07, 2020  (GLOBE NEWSWIRE) --  Biomerica Inc. (NASDAQ: BMRA) today announced that Houston Methodist (part of Texas Medical Center, the largest medical complex in the world) will start enrollment  for the clinical trial of its new InFoods® diagnostic-guided therapy (DGT) to alleviate Irritable Bowel Syndrome (IBS) symptoms. Houston Methodist will join Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, and the University of Michigan as primary enrollment centers for this study.

Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods® Irritable Bowel Syndrome (IBS) diagnostic guided therapy clinical trial

IRVINE, Calif., Oct.  16, 2019  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,194,415 for the three months ending August 31, 2019, compared to $1,272,870 for the same period in the previous year.   Net loss for the three months ended August 31, 2019 was $506,296 compared to a net loss of $451,740 during the same period in fiscal 2019. Research and development for the three months ending August 31, 2019, was $370,466 compared to $391,781 for the same period in the previous year.  “Although revenues in Q1 2020 were slightly lower than the prior year, we expect sales of our specialty diagnostics to begin increasing in Q2, as compared to the same quarterly sales in the previous year," said Zackary Irani, CEO of Biomerica, Inc. “We also expect to be near completion of the enrollment of patients for clinical trials for our H. Pylori diagnostic product in fiscal Q2 and plan to submit to the FDA shortly thereafter. Once approved, the H. Pylori product should contribute significantly to our revenues. Further, during Q2 we plan to announce important progress in the clinical trials for our diagnostic guided therapy, InFoods® technology, which we expect to make a significant impact on some of the 45 million Americans who suffer from Irritable Bowel Syndrome (IBS). We are expecting to hit several major milestones at Biomerica over the next 12 months, and are excited to see the impact these milestones will have on shareholder value."

Biomerica Reports 1st Quarter Fiscal 2020 Financials

IRVINE, Calif., Aug.  30, 2019  (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682 versus net sales of $5,564,185 in fiscal 2018. Net loss was $2,393,060 for fiscal 2019 compared to net loss of $1,465,828 for fiscal 2018. Research and Development investment was $1,679,098 for fiscal year 2019 compared to $1,398,368 the previous year, an increase of $280,730, or 20%.

Biomerica Announces Fiscal Year End 2019 Financial Results

Biomerica also adds new director of sales and marketing for Europe and South America Biomerica also adds new director of sales and marketing for Europe and South America

News for Biomerica Stock (BMRA)